<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00311558</url>
  </required_header>
  <id_info>
    <org_study_id>CASE-CCF-7059</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CCF-7509</secondary_id>
    <secondary_id>CASE-CCF-1062</secondary_id>
    <secondary_id>CASE 2Y06</secondary_id>
    <nct_id>NCT00311558</nct_id>
  </id_info>
  <brief_title>Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma</brief_title>
  <official_title>Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b for Solid Tumors, Lymphoma or Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sodium stibogluconate may stop the growth of cancer cells by blocking some of the&#xD;
      enzymes needed for cell growth. Interferon may interfere with the growth of cancer cells.&#xD;
      Giving sodium stibogluconate together with interferon may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of sodium&#xD;
      stibogluconate when given together with interferon in treating patients with advanced solid&#xD;
      tumors, lymphoma, or myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Confirm the tolerance, safety, and maximum tolerated dose of sodium stibogluconate (SSG)&#xD;
           in combination with interferon alfa-2b in patients with advanced solid tumors, lymphoma,&#xD;
           or myeloma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Quantify the effect of SSG on interferon alfa-2b-induced gene modulation and signal&#xD;
           transduction pathways by measurement of the serum-soluble gene products β-2&#xD;
           microglobulin, immune serum globulin 15, and neopterin.&#xD;
&#xD;
        -  Define the effectiveness of SSG in inhibiting the protein tyrosine phosphatases src&#xD;
           homology proteins (SHP)-1 and SHP-2 assayed from peripheral blood leukocytes of patients&#xD;
           receiving SSG in combination with interferon alfa-2b.&#xD;
&#xD;
        -  Define pharmacokinetics of SSG in serum at escalating doses.&#xD;
&#xD;
        -  Assess clinical response to the combination of SSG and interferon alfa-2b.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of sodium stibogluconate (SSG).&#xD;
&#xD;
      Patients receive SSG IV over 15 minutes on days 1, 15-19, and 22-26 and interferon alfa-2b&#xD;
      subcutaneously daily on days 8-12 and 15-28. Treatment repeats every 6 weeks in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 6 patients receive escalating doses of SSG until the maximum tolerated dose (MTD)&#xD;
      is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance, safety, and maximum tolerated dose at 1 week after each course</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>SSG &amp; INF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 arm study: SSG &amp; interferon</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa-2b</intervention_name>
    <description>SSG x 5 week</description>
    <arm_group_label>SSG &amp; INF</arm_group_label>
    <other_name>Sodium Stibocluconate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium stibogluconate</intervention_name>
    <description>SSG &amp; IFN</description>
    <arm_group_label>SSG &amp; INF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSG &amp; interferon</intervention_name>
    <description>1 arm study with SSG &amp; interferon</description>
    <arm_group_label>SSG &amp; INF</arm_group_label>
    <other_name>Sodium Stiboglucante</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignancy, including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Renal cell carcinoma&#xD;
&#xD;
               -  Melanoma&#xD;
&#xD;
               -  Kaposi's sarcoma&#xD;
&#xD;
               -  Breast, prostate, colorectal, or lung adenocarcinoma&#xD;
&#xD;
               -  Bone and soft tissue sarcomas&#xD;
&#xD;
               -  Lymphoma&#xD;
&#xD;
               -  Myeloma&#xD;
&#xD;
               -  Tumors of neuroendocrine and endothelial cell origin&#xD;
&#xD;
          -  Stage IV disease&#xD;
&#xD;
          -  Refractory disease, resistant to established treatments, or no effective treatment&#xD;
             available&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  CNS metastases allowed if no prior definitive therapy within the past 3 months and no&#xD;
             glucocorticoids required&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Granulocyte count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Creatinine &lt; 1.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
          -  AST/ALT &lt; 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No history of any of the following:&#xD;
&#xD;
               -  Atrial fibrillation, atrial flutter, or other serious arrhythmia (excluding&#xD;
                  asymptomatic atrial and ventricular premature complexes)&#xD;
&#xD;
               -  Congestive heart failure currently requiring treatment&#xD;
&#xD;
               -  Angina pectoris&#xD;
&#xD;
               -  Other severe cardiovascular disease (i.e., New York Heart Association class III&#xD;
                  or IV heart disease)&#xD;
&#xD;
          -  No baseline ECG abnormalities suggestive of cardiac conduction delay, i.e., 1° or&#xD;
             greater atrio-ventricular block and/or complete or incomplete (QRS &gt; 120 ms) bundle&#xD;
             branch block, or repolarization abnormalities (i.e., QTc ≥ 0.48 sec)&#xD;
&#xD;
          -  No systemic infections requiring antibiotics within the past 14 days&#xD;
&#xD;
          -  No known hepatitis B surface antigen positivity&#xD;
&#xD;
          -  Psychologically prepared to participate in study treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior interferon (IFN) therapy and/or ≤ 400 million units of&#xD;
             IFN&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery&#xD;
&#xD;
          -  At least 3 weeks since prior radiation therapy or chemotherapy&#xD;
&#xD;
          -  No prior solid organ allografts or allogeneic bone marrow transplantation&#xD;
&#xD;
          -  No concurrent daily glucocorticoids except for physiological replacement&#xD;
&#xD;
          -  No other concurrent medications known to prolong QT interval&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernest C. Borden, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>April 5, 2006</study_first_submitted>
  <study_first_submitted_qc>April 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2006</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV melanoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Antimony Sodium Gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

